The Hematology Society of Taiwan yesterday said acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, can progress quickly and aggressively and urged the government to ...

Precision Biologics, Inc. announces a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented ...

Know AML will mark AML World Awareness Day on Tuesday April 21, 2026, uniting patients, caregivers, societies, and the wider community to raise awareness of acute myeloid leukemia (AML). Many people ...

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...

Orum's New Preclinical Data at AACR 2026 on ORM-1153 Highlights Broad Activity in AML and the Potential for Improved Efficacy ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Delta-Fly Pharma Inc. is pressing ahead with discussions with the FDA for its lead acute myeloid leukemia (AML) candidate, radgocitabine (DFP-10917), despite a phase III miss on its primary endpoint, ...

Serial post-transplant chimerism assessment provided more reliable prognostic insight than a single early measurement.

Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers ...